title: Taxol administration.
abstract: The majority of patients with ovarian cancer have widespread abdominal disease. Before 1970, the response rate for patients treated with chemotherapeutic agents was less than 10%. With the introduction of cisplatin, the response rate tripled. However, patients treated with repeated courses of platinum-containing regimens may develop resistance to this form of therapy. Taxol (Bristol Laboratories, Princeton, NJ), a new drug, has been shown to be an effective agent in patients who have failed first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary even in women with platinum-resistant disease.
authors.forename: C
authors.initials: C
authors.lastname: Rutherford
mesh_terms: D004351:Drug Resistance; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000451:nursing; D017239:Paclitaxel / Q000627:therapeutic use*; D010347:Patient Care Planning
chemical_list: D017239:Paclitaxel